Background The expression level of signal transducer and activator of transcription 3 (STAT3) in tumor cells is reported to associate with response to therapy and with survival time in various types of cancer. Objective This retrospective study aimed to elucidate the association of STAT3 expression in tumor cells with the therapeutic outcomes of sunitinib in patients with renal cell carcinoma (RCC). Patients and Methods Patients with metastatic RCC who received sunitinib therapy were enrolled in this study. All patients underwent nephrectomy for RCC, and nephrectomy specimens were stained for STAT3 and phosphorylated STAT3 (p-STAT3) by immunohistochemistry. Results We assessed 51 patients receiving sunitinib as a first-line therapy. STAT3 expression levels did not influence progressionfree survival (PFS) and overall survival (OS); however, patients with p-STAT3-positive tumors exhibited significantly worse PFS compared with those with p-STAT3-negative tumors (log-rank test, P = 0.034). OS tended to be prolonged in patients with p-STAT3-negative tumors. Objective response rate or disease control rate based on the best overall response did not show a significant association with STAT3 or p-STAT3 expression. Univariate Cox proportional hazard regression analyses for clinical predictors revealed that p-STAT3 positivity significantly correlated with shorter PFS (hazard ratio [HR], 2.22, P = 0.041), whereas p-STAT3 expression was not related to the OS. Conclusions Activated STAT3 in tumor tissues shows a significant association with poor prognosis in patients with RCC who received sunitinib as a first-line therapy, and positive p-STAT3 expression could be a potential biomarker for refractoriness to sunitinib therapy.
Introduction
Multiple tyrosine kinase inhibitors (mTKIs) are the standard therapeutic option for patients with renal cell carcinoma (RCC) and are known to extend the progression-free survival (PFS) and overall survival (OS) significantly compared to interferon therapy in patients with metastatic RCC (mRCC) [1, 2] . According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Kidney Cancer, sunitinib is a first-line therapy option for patients with mRCC with a good performance status (PS) [3] . However, approximately 20% of patients receiving sunitinib in this setting do not respond to treatment [1] . In addition, sunitinib has been reported to be severely toxic, leading to complications including hematological disorders, diarrhea, and fatigue. Thus, determining prognostic and individualized markers to ensure its safety and efficacy is imperative. Although several prognostic markers have been reported in patients with RCC receiving sunitinib, no clinical application of prognostic factors signifying the tumor cell profile has been reported.
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is activated by growth factors and cytokines through phosphorylation by receptor or non-receptor tyrosine kinases [4] . STAT3 plays an important role in the proliferation, apoptosis, and migration of cancer cells and it is an important target for cancer therapy [5] [6] [7] . In addition, preliminary studies have suggested that the inhibition of STAT3 activation is one of the antitumor effects of sunitinib [8] [9] [10] [11] . Moreover, STAT3 is known to play a role in the mechanism of resistance to sunitinib in tumor cells [12] . In particular, STAT3 decreases the intracellular accumulation of sunitinib by enhancing Pglycoprotein expression. In addition, several previous reports suggest that genetic polymorphisms in STAT3 are correlated to the therapeutic outcomes of interferon therapy in Japanese patients with RCC [13, 14] . In our previous study, we reported that genetic polymorphisms in STAT3 are associated with the overall response to mTKIs therapy in patients with RCC [15] . Hence, we further hypothesized that specific polymorphisms associated with lower STAT3 protein expression could be associated with a better prognosis following chemotherapy in patients with RCC. Although genomic DNA extracted from peripheral blood was analyzed in these studies, the correlation of actual STAT3 expression levels in tumor cells with therapeutic outcomes of sunitinib remains unclear.
This retrospective analysis using nephrectomy specimens from patients with RCC aims to elucidate the correlation between actual STAT3 and activated STAT3 expression level in tumor cells and clinical outcomes after sunitinib therapy.
Materials and Methods

Patients
In this study, we retrospectively examined 62 consecutive patients with mRCC who were treated with sunitinib at the Department of Urology, Kobe University Hospital (Kobe, Japan) between January 2013 and December 2014. All enrolled patients underwent radical nephrectomy for RCC and initially received either 50 mg once daily in repeated 6-week cycles comprising 4 weeks on treatment followed by 2 weeks off treatment. The sunitinib administration was continued until disease progression or intolerable adverse events (AEs) occurred. As a rule, dose modification was considered in patients with treatment-associated AEs that were grade-3 or higher as follows: the initial sunitinib dose was reduced from 50 to 37.5 mg once daily and then to 25 mg once daily and patients who failed sunitinib treatment before the evaluation using computed tomography (CT) were excluded from the analysis of the best overall response. This study protocol was approved by the ethics committee at Kobe University Graduate School of Medicine, and we obtained informed consent from each enrolled patient. The medical records of all patients were collected in cooperation with an attending urologist. In addition, all procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Immunohistochemical Staining
We used nephrectomy sections from the RCC operation in this study, and formaldehyde-fixed, paraffin-embedded tissue was deparaffinized and rehydrated. After blocking endogenous peroxidase activity, sections were incubated with STAT3 and phosphorylated STAT3 (p-STAT3) antibodies (Cat. No. #8768 and #9145; Cell Signaling Technology, Boston, MA, USA) overnight at 4°C. Next, the samples were incubated with the corresponding secondary antibodies (Vector Laboratories, Burlingame, CA, USA) for 30 min at room temperature. After incubation in an avidin-biotin-peroxidase complex, we exposed the sections to diaminobenzidine tetrahydrochloride solution and counterstained with hematoxylin. Staining findings were interpreted and scored by two independent observers who were blinded to the clinicopathological data of patients. Positive staining for STAT3 or p-STAT3 in ≧50% of tumor cells was indicative of positive expression with reference to a previous study that evaluated pSTAT3 immunohistochemistry of histological specimens [16, 17] .
Evaluation of Clinical Outcomes with Sunitinib
Baseline evaluations at the start of a first-line therapy with sunitinib comprised the PS and clinicopathological examinations, which were assessed on the basis of the Karnofsky PS scale. In addition, risk classification was performed using the Memorial Sloan-Kettering Cancer Center (MSKCC) score for mRCC [18, 19] . Before the introduction of sunitinib, all patients were evaluated through radiological examinations, including CT of the brain, chest, and abdomen, or radionuclide bone scans, or both. Typically, tumor measurements were performed using CT every 8-12 weeks after initiating sunitinib therapy. All responses and AEs were assessed by a treating physician based on the Response Evaluation Criteria in Solid Tumors version 1.1 and the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0, respectively.
Statistical Analysis
Categorical data across groups in this study was compared using the Fischer's exact test. Continuous data across groups was compared using the unpaired Student's t-test. In addition, the PFS and OS were calculated using the Kaplan-Meier method, and significant differences were determined using the log-rank test. The significance of predictive factors was assessed using the Cox proportional hazards regression model. Furthermore, we considered P < 0.05 (two-tailed) as statistically significant in this study. All statistical analyses were performed using SPSS software version 24.
Results
Patient Characteristics According to STAT3 or P-STAT3 Expression Patterns
In this study, we enrolled 62 patients (Fig. 1) . However, timeto-event analyses were performed with 51 patients after excluding those treated with sunitinib post-first-line therapy. In addition, the best overall response analysis was performed in 48 patients after excluding patients who failed sunitinib treatment prior to diagnosis using CT. Immunohistochemical staining revealed that positive p-STAT3 expression and positive STAT3 expression were observed in 14 (27.5%) and 22 patients (43.1%), respectively. Figure 2 shows representative images of immunohistochemical staining, and Table 1 represents the characteristics of 51 patients according to the STAT3 and p-STAT3 expression patterns. Patients with the positive p-STAT3 expression had a lower body mass index (BMI; P = 0.037) relative to the findings in patients with negative p-STAT3 expression.
Association of STAT3 and P-STAT3 Expression in Tumor Cells with Treatment Outcomes
In this study, the median PFS and OS in 51 patients were 10.3 (95% confidence interval [CI]: 5.8-16.3) and 38.0 (95% CI: 15.4 to not reached) months, respectively. Figure 3 shows the Kaplan-Meier curves for PFS and OS according to STAT3 and p-STAT3 expression levels. We observed no significant difference in PFS and OS between the positive and negative STAT3 expression groups; however, patients with positive p-STAT3 expression exhibited significantly shorter PFS than those with negative p-STAT3 expression (P = 0.037). In addition, p-STAT3 negativity correlated with a prolonged OS, although the differences were not statistically significant. Furthermore, we observed no significant associations of objective response and disease control rates based on the best overall response with STAT3 or p-STAT3 expression levels ( Table 2 ).
Predictive Effects of STAT3 or P-STAT3 Expression on PFS and OS
Univariate Cox proportional hazards regression analyses for PFS and OS revealed that positive p-STAT3 expression was significantly associated with a shorter PFS; multiple metastatic sites and poor MSKCC risk were also associated with shorter PFS (Table 3) . Younger age, lower BMI, and poor MSKCC risk significantly correlated with shorter OS, while p-STAT3 expression did not show a significant association with shorter OS. Multivariate analyses for evaluation of predictive factors for PFS and OS were not performed because of the small sample size of this study. 
Discussion
STAT3 is activated by phosphorylation and enhances the transcription of target genes related to cell proliferation, apoptosis suppression, and migration [5] . Reportedly, the apoptosis-and cell growth-inhibiting effects of sunitinib were reduced in constitutively-active STAT3-transfected RCC cell lines and enhanced in STAT3-knockdown RCC cells [10] . Our current study supports the previous findings and demonstrates that activated STAT3, but not total STAT3, expression in tumor cells is correlated to a shorter PFS of sunitinib therapy in patients with RCC. In contrast, the OS did not significantly differ between the positive and negative p-STAT3 expression groups, although the OS in the early phase after the initiation of sunitinib was significantly higher in p-STAT3-negative patients compared with that in p-STAT3-positive patients. This study included patients treated with sunitinib therapy as a firstline RCC therapy, and most p-STAT3-positive patients progressed within 10 months of sunitinib therapy, after which they went on to further lines of therapy. Moreover, there were no significant associations in the objective response and disease control rates based on the best overall response with STAT3 or p-STAT3 expression levels. Thus, positive p-STAT3 expression predicts the refractoriness to sunitinib therapy in an early phase. p-STAT3 may be a factor for refractoriness rather than a factor for responsiveness because p-STAT3 is also associated with chemotherapy resistance and migration relating to EMT. In addition, some studies have suggested the correlation between p-STAT3 levels in RCC specimens and survival times for patients with RCC regardless of the type of treatment [17, 20] . In addition, survival times in patients with prostate cancer are demonstrated to be associated with p-STAT3 levels more than in patient with RCC [21] . Perhaps, the p-STAT3 tumor expression level could be a prognostic marker in various types of cancers. These studies corroborate our hypothesis that p-STAT3 could possibly predict the OS after sunitinib therapy in RCC. Our previous study revealed that functional singlenucleotide polymorphisms (SNPs) that can potentially lower STAT3 expression are associated with the good overall best response or short time to response with TKI therapy for mRCC, but not with PFS [15] . However, our current study demonstrates that the STAT3 expression in tumors was not related to the best overall response to sunitinib therapy. In addition, our previous study determined that functional SNPs in STAT3 did not correlate with the tumor expression of STAT3 in patients with RCC (data not shown). Thus, these findings suggest that genomic polymorphisms of STAT3 do not affect STAT3 tumor expression. The correlation of functional STAT3 SNPs with treatment response to sunitinib could be illustrated by the difference of the STAT3 expression in systemic immune cells according to the polymorphism; however, further studies are warranted to certify this hypothesis. STAT3 activation in tumor cells is induced by interleukin (IL)-6 [22] . Some studies have reported that higher serum IL-6 levels induced resistance to sunitinib and resulted in worse OS and PFS [23, 24] . Tumor p-STAT3 expression could be a response to higher serum IL-6 levels, causing sunitinib resistance. In addition, the IL-6-STAT3 pathway activation induces the epithelial-mesenchymal transition (EMT), which is a crucial process for sunitinib resistance and acquirement of the migratory mesenchymal phenotype in RCC [25, 26] . Thus, association with the STAT3 activation and prognosis of sunitinib therapy could mediate the EMT process; however, further investigation is needed to verify this hypothesis.
The median PFS among 51 patients who received first-line sunitinib therapy in this study was 10.3 months, which corroborated the median PFS (11 months) in patients with RCC who received first-line sunitinib therapy in an international, multicenter, randomized, phase III trial [27] . In contrast, the median OS in this study was 38 months, although it was 26.4 months in the aforementioned international trial. Apparently, the therapeutic outcome of sunitinib is better in Japanese patients than in other populations. Phase II trials of Japanese patients with untreated RCC demonstrated that the median PFS and OS were 12.2 and 33.1 months, respectively [28, 29] , which was consistent with our study. In addition, Japanese patients with mRCC currently have more options after a first-line therapy than those available when the international trial was conducted. Perhaps these findings could explain the longer OS observed in our study.
MSKCC scores are classified on the basis of poor prognostic factors for cytokine therapy, and some studies suggested that the MSKCC risk is also associated with the prognosis of sunitinib therapy in clear-cell RCC, but not other histologies [27, 30] . In this study, we could not establish a significant correlation between the PFS and the MSKCC risk score because patients with non-clear-cell RCC were also enrolled in this study. In addition, the presence of multiple metastatic sites correlated with a poor prognosis for sunitinib therapy [27, 31] . Younger patients exhibited poor prognoses following sunitinib therapy in our univariate analysis to assess predictive factors for the OS. This is in line with a recent subgroup analysis and updated OS results from the Sunitinib Treatment Of Renal Adjuvant Cancer (S-TRAC) study, in which sunitinib was tested as an adjuvant treatment, where patients aged 45-64 years who were treated with sunitinib did not experience superior outcomes compared to placebo-treated patients [32] . Some studies have reported that patients with RCC and lower BMI exhibited poorer cancer-specific survival [33] . As described previously, the association of known prognostic factors with the OS in this study supported the published data.
This study has several limitations. First, this was a smallsample, retrospective study. Thus, multivariate analysis of various parameters as predictors of the PFS and OS were not performed. In addition, the study protocol was not adequate to obtain definitive conclusions. Second, poorly standardized and validated procedures of STAT3 immunohistochemical staining were used in this study. The immunohistochemical analysis could be typically affected by the variation in antibodies and thresholds for judgment of positive expression. Finally, immunostaining was performed using primary tumor specimens, although metastatic tumor specimens would be more suitable for investigating the correlation between mTKI therapeutic outcomes and the expression of specific factors.
In conclusion, activated STAT3 in tumor tissues shows significant correlation with poor prognosis in patients with RCC who received sunitinib as a first-line therapy. In addition, the positive p-STAT3 expression is likely correlated with a shorter OS in the early treatment phase. Hence, this study suggests that the STAT3 activation in tumor tissues could be a predictive marker of refractoriness to sunitinib therapy in patients with mRCC.
